About Perceptive Advisors
Perceptive Advisors is a venture capital firm founded in 1999. It is primarily based out of New York City, United States. As of May 2026, Perceptive Advisors is an active investor, having invested in 209 companies, with 3 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Post IPO round of Quince Therapeutics Overall, Perceptive Advisors portfolio has seen 4 unicorns, 92 IPOs and 54 acquisitions including key companies like BridgeBio, Omada and Invitae. A lot of funds co-invest with Perceptive Advisors, with names like RA Capital Management sharing a substantial percentage of its portfolio. Perceptive Advisors has team of 40 people including 11 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Post IPO & 9 more
Portfolio IPOs
Portfolio Unicorns
Portfolio Soonicorns
Deals in last 12 months
Perceptive Advisors' List of Top Investments
Perceptive Advisors has a portfolio of 209 companies, including 4 unicorns. Their most notable investments are in Kindbody and Cidara Therapeutics.Their portfolio spans across United States, United Kingdom, Canada and 8 more locations. They have invested in Life Sciences, High Tech, HealthTech and 12 other sectors, across stages such as Series B, Post IPO and 9 more. Here is the list of top investments by Perceptive Advisors:
1. BridgeBio
Developer of therapeutics for the treatment of genetic diseases. It utilizes a mapping of various genetic disease landscapes to identify opportunities for therapeutic intervention. The company's drug candidates include PTCH1-inhibitor for Gorlin syndrome and S1P-lyase inhibitor for Darier disease and Hailey-Hailey disease and others.
Key facts about BridgeBio
- Founded Year: 2015
- Location: Palo Alto (United States)
- Annual Revenue: $502M as on Dec 31, 2025
- Stage: Acquired
- Total Funding till date: $434M
- Employee Count: 948 as on Apr 30, 2026
- Investors: Wellington, Deerfield and 20 Others
- Latest Funding Round: Post IPO, Apr 30, 2024, $*****
- Highlight: Acquired
2. Omada
Provider of virtual care programs to manage chronic diseases. The company provides access to personal health coaches and specialists for virtual programs to deliver personalized interventions for prediabetes, diabetes, hypertension, and musculoskeletal issues.
Key facts about Omada
- Founded Year: 2011
- Location: San Francisco (United States)
- Stage: Public
- Total Funding till date: $450M
- Employee Count: 987 as on May 31, 2026
- Investors: Fidelity Investments, New Enterprise Associates and 44 Others
- Latest Funding Round: Series E, Feb 23, 2022, $*****
- Highlight: Public
3. Invitae
Provider of home-based genetic tests for individuals. The platform enables users to request a test online with the help of doctors to collect saliva samples to detect genetic diseases. Users can get results online and share them with doctors.
Key facts about Invitae
- Founded Year: 2010
- Location: San Francisco (United States)
- Annual Revenue: $516M as on Dec 31, 2022
- Stage: Public
- Total Funding till date: $190M
- Employee Count: 684 as on May 31, 2026
- Investors: Scheuermann Investment, Wellington and 22 Others
- Latest Funding Round: Post IPO, Apr 05, 2021, $*****
- Highlight: Public
4. Biodesix
Developer of diagnostics assays for the detection of cancer. The company offers invitro-diagnostic tests including Nodify Lung testing consisting of two blood-based proteomic tests, to identify the risk of malignancy of a lung nodule, and GeneStrat NGS a broad tumor mutation testing.
Key facts about Biodesix
- Founded Year: 2005
- Location: Boulder (United States)
- Annual Revenue: $88.5M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $200M
- Employee Count: 354 as on May 31, 2026
- Investors: Lincoln Park Capital, Perceptive Advisors and 1 Other
- Latest Funding Round: Post IPO, Nov 23, 2022, $*****
- Highlight: Public
Developer of small molecule therapeutics for treating cancer and rare diseases. The company's lead drug Nirogacestat (PF-03084014), a gamma-secretase inhibitor that helps in treating non-metastatic tumors of connective tissue cells. The second candidate is a MEK 1/2 inhibitor, PF-0325901, for the genetic disorder NF1, one of three genetic conditions known as neurofibromatosis. The 3rd candidate, senicapoc (PF-05416266), also targets a rare condition, hereditary xerocytosis characterized by dehydrated red blood cells.
Key facts about SpringWorks Therapeutics
- Founded Year: 2017
- Location: New York City (United States)
- Annual Revenue: $192M as on Dec 31, 2024
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $230M
- Employee Count: 382 as on May 31, 2026
- Investors: Boxer Capital, BVF Partners and 17 Others
- Latest Funding Round: Post IPO, Sep 07, 2022, $*****
- Highlight: Acquired
Perceptive Advisors' Year-on-Year Investment Trends
Perceptive Advisors has invested in 210 companies over the last 19 years, with an average of 16 new investments annually in the last 10 years. In 2025, it made 5 investments, while as of May 2026, it has made 5 investments in this year. Its most recent first time investment was in Quince Therapeutics and most recent follow-on round was in Alto Neuroscience.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 2 | 3 | 5 |
2025 | 3 | 2 | 5 |
2024 | 15 | 7 | 22 |
2023 | 5 | 4 | 9 |
2022 | 7 | 8 | 15 |
2021 | 29 | 7 | 36 |
2020 | 29 | 13 | 42 |
2019 | 26 | 6 | 32 |
2018 | 22 | 4 | 26 |
2017 | 12 | 2 | 14 |
Perceptive Advisors' Investments by Stage
Perceptive Advisors has made 54 investments in Series B stage with an average round size of $82.8M, 38 investments in Post IPO stage with an average round size of $107M and 25 investments in Series A stage with an average round size of $71.3M.Stage of entry | No. of Investments |
|---|---|
Series B | 54 |
Post IPO | 38 |
Series A | 25 |
Series C | 24 |
Conventional Debt | 15 |
Others | 28 |
Note: We have considered here, only first round of investments
Perceptive Advisors' Investments by Sector
Perceptive Advisors has a diverse portfolio, with companies operating in the Life Sciences, High Tech, HealthTech, Healthcare and Enterprise Applications. Notably, it has invested in 185 Tech companies, 178 Enterprise (B2B) companies, 26 Software companies and at least 23 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 160 |
High Tech | 36 |
HealthTech | 22 |
Healthcare | 15 |
Enterprise Applications | 14 |
Others | 37 |
Note: We have considered here, only first round of investments
Perceptive Advisors' Investments by Geography
Perceptive Advisors has made most investments in United States (157), followed by United Kingdom where it has made 8 investments.Country | No. of Investments |
|---|---|
United States | 157 |
United Kingdom | 8 |
Canada | 6 |
France | 4 |
Israel | 3 |
Others | 6 |
Note: We have considered here, only first round of investments
Perceptive Advisors' recent investments
Perceptive Advisors has made 5 investments in 2026 so far. Quince Therapeutics and Alto Neuroscience are the latest among them.Here are the most recent investments by Perceptive Advisors:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
May 18, 2026 | United States | Post IPO | 6789 | ||
Mar 16, 2026 | United States | Post IPO | 6786 | [+5] | |
Mar 13, 2026 | United States | Series E | 4498 | ||
Mar 06, 2026 | United States | Post IPO | 5447 | ||
Feb 12, 2026 | United States | Series D | 7939 | [+3] |
Unicorns in Perceptive Advisors' Portfolio
Perceptive Advisors has 4 unicorns in its portfolio - Kindbody, Freenome Health, Honor and others. The most recent unicorn in their portfolio is Kindbody. It became a unicorn in 2022, 2 years after Perceptive Advisors first invested in it.Here is a list of unicorns in Perceptive Advisors' portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
53 | Provider of fertility services for women | 2018 | New York City | Series D | kqtmadi | ||
66 | Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | - | Series E | gaqdqiz | ||
72 | Provider of home care and senior care services | 2014 | Omaha | Series E | hqfbsfa | ||
70 | Provider of MR-interfaced ultrasound technology-based device for cancer and neurology | 1999 | Tirat Carmel | Series G | gvrjfvi |
IPOs and Publicly Listed companies in Perceptive Advisors' Portfolio
92 of Perceptive Advisors' portfolio companies have become public. Avalyn Pharma got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Apr 2026 at marketcap of $753M and Vyome Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ).Here are Perceptive Advisors' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Apr 30, 2026 | Sep 27, 2023 | Series C | 1694 | |
Aug 15, 2025 | Jul 26, 2016 | Series C | 4285 | |
Jun 18, 2025 | Apr 07, 2025 | Series D | 4359 | |
Jun 06, 2025 | May 19, 2020 | Series D | 2830 | |
Feb 07, 2025 | Mar 06, 2024 | Series C | 7161 |
Acquired companies in Perceptive Advisors' Portfolio
54 companies from Perceptive Advisors' portfolio have been acquired. The most recent acquisition was Day One in Mar 2026 by Servier for $*****.Here are Perceptive Advisors' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 06, 2026 | Feb 01, 2021 | Series B | 8195 | |
Jan 20, 2026 | Dec 23, 2024 | Post IPO | 1626 | |
Nov 14, 2025 | Feb 13, 2015 | Series B | 4833 | |
Oct 27, 2025 | Nov 13, 2019 | Series C | 7367 | |
Oct 14, 2025 | Jan 29, 2021 | Post IPO | 2843 |
Team profile of Perceptive Advisors
Perceptive Advisors has a team of 40 members including 11 Partners and 9 Principals located in United States. Perceptive Advisors' team sits on the board of 1 company.Here is a list of top team members in Perceptive Advisors:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | New York City | - | - | |
Partner | New York City | - | - | |
Partner | New York City | - | - | |
Partner | New York City | - | - | |
Partner | New York City | - | - | |
Partner | New York City | - | - | |
Partner | Mobile | - | - | |
Partner | Boston | - | ||
Partner | - | - | - | |
Partner | New York | - | - | |
Partner | - | - | - |
Co-investors of Perceptive Advisors
Over the past 19 years, 1176 investors have co-invested in Perceptive Advisors's portfolio companies. This includes funds and angels.
- Invested before Perceptive Advisors: HHS, Orbimed and 580 others have invested in rounds before Perceptive Advisors. There are 24 companies where HHS has invested before Perceptive Advisors and 15 companies where Orbimed has invested before Perceptive Advisors.
- Top Co-investors of Perceptive Advisors: 344 investors entered a company along with Perceptive Advisors. These include investors like RA Capital Management (32 companies).
- Invested after Perceptive Advisors: A total of 250 investors have invested in Perceptive Advisors's portfolio after their investments. Top Investors include Fidelity Investments (8 companies), EcoR1 (7 companies) and Citadel (6 companies).
Recent News related to Perceptive Advisors
•
Adlai Nortye Announces $150.0 Million Private PlacementGlobeNewswire•Apr 16, 2026•Perceptive Advisors, Soleus Capital, Adlai Nortye
•
Imperative Care Raises $100M in FundingFinSMEs•Mar 18, 2026•Patient Square Capital, Imperative Care, Bain Capital Life Sciences, Perceptive Advisors and 7 others
•
•
Medincell Announces Private PlacementFortuneo•Mar 05, 2026•MedinCell, Affinity Asset Advisors, Perceptive Advisors, Kurma Partners and 1 other
•
Talkiatry Announces $210M Series D RoundMassinvestor•Feb 13, 2026•Talkiatry, Perceptive Advisors, Andreessen Horowitz, Left Lane and 3 others
•
Trinity Biotech Secures Agreements to Bolster Capital Structure and Fuel GrowthGlobeNewswire•Dec 23, 2025•Trinity Biotech, Perceptive Advisors
•
Impulse Dynamics Completes $158M Financing RoundAgencia EFE•Dec 10, 2025•Impulse Dynamics, Braidwell, Sands Capital, Perceptive Advisors and 3 others
•
•
•
Alto Neuroscience Announces $50 Million Private Placement Financingintelligence360•Nov 10, 2025•Vestal Point Capital, Alto Neuroscience, Perceptive Advisors, Commodore Capital and 1 other
